Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1Neuroblastoma 1Multiple Endocrine Neoplasia 1Carcinoid Tumor 1Adrenal Gland Neoplasms 1

Interventions

3-Iodobenzylguanidine 7gallium Ga 68 dotatate 4fluorodopa F 18 3pegfilgrastim 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Granulocyte Colony-Stimulating Factor 23-fluorobenzylguanidine 2tipifarnib 1pertuzumab 1pentetreotide 1olaparib 1lutetium Lu 177 dotatate 1entrectinib 1cixutumumab 1arginyllysine 1Whole Body Imaging 1Vorinostat 1Tretinoin 1Stem Cell Transplantation 1Potassium Iodide 1Nivolumab 1Leucovorin 1LY2940680 1Isotretinoin 1Furosemide 1Floxuridine 1Erlotinib Hydrochloride 1Cytoreduction Surgical Procedures 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × (18F)GTP1 × Endocrine × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡